MT 3995

Drug Profile

MT 3995

Alternative Names: MT-3995

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Antihypertensives
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Non-alcoholic steatohepatitis
  • Discontinued Hypertension

Most Recent Events

  • 02 Oct 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in Japan (PO) before October 2016 (NCT02923154)
  • 01 Aug 2016 Phase-I clinical trials in Diabetic nephropathies (In volunteers) in United Kingdom (PO) (NCT02900235)
  • 01 Feb 2016 Mitsubishi Tanabe Pharma initiates enrolment in a phase II extension trial for Diabetic nephropathy in Japan (NCT02676401)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top